白细胞介素2受体
癌症研究
免疫疗法
抗体
效应器
生物
下调和上调
封锁
肿瘤浸润淋巴细胞
免疫检查点
单克隆抗体
癌症免疫疗法
免疫系统
细胞
受体
免疫学
T细胞
生物化学
基因
作者
Frederick Arce Vargas,Andrew J.S. Furness,Isabelle Solomon,Kroopa Joshi,Leila Mekkaoui,Marta H. Lesko,Enrique Miranda,Rony Dahan,Andrew Georgiou,Anna Śledzińska,Assma Ben Aïssa,Dafne Franz,Mariana Werner Sunderland,Yien Ning Sophia Wong,Jake Y. Henry,Tim O’Brien,David Nicol,Ben Challacombe,Stephen A. Beers,Samra Turajlic
出处
期刊:Immunity
[Cell Press]
日期:2017-04-01
卷期号:46 (4): 577-586
被引量:388
标识
DOI:10.1016/j.immuni.2017.03.013
摘要
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We demonstrated that CD25 expression is largely restricted to tumor-infiltrating Treg cells in mice and humans. While existing anti-CD25 antibodies were observed to deplete Treg cells in the periphery, upregulation of the inhibitory Fc gamma receptor (FcγR) IIb at the tumor site prevented intra-tumoral Treg cell depletion, which may underlie the lack of anti-tumor activity previously observed in pre-clinical models. Use of an anti-CD25 antibody with enhanced binding to activating FcγRs led to effective depletion of tumor-infiltrating Treg cells, increased effector to Treg cell ratios, and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies promoted complete tumor rejection, demonstrating the relevance of CD25 as a therapeutic target and promising substrate for future combination approaches in immune-oncology.
科研通智能强力驱动
Strongly Powered by AbleSci AI